Post-earnings recap
Reported
Wed, May 8, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss per share of $0.41, with no revenue figures disclosed. Despite the EPS miss, the stock saw a slight increase of 0.13%, likely driven by positive sentiment around their ongoing clinical trials and management's optimistic outlook. Investors may be encouraged by the company's focus on long-term growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about their clinical developments. They are focused on long-term goals while navigating current financial challenges.
Management highlighted ongoing progress in their clinical trials.
They emphasized a commitment to advancing their pipeline despite current losses.